Valuation : Rezolute Inc

Market Cap 483M 416M 390M 356M 671M 46.13B 673M 4.63B 1.81B 23.28B 1.81B 1.77B 77.21B P/E 2026 *
-6.6x
P/E 2027 * -7.11x
Enterprise Value 483M 416M 390M 356M 671M 46.13B 673M 4.63B 1.81B 23.28B 1.81B 1.77B 77.21B EV / Sales 2026 *
-
EV / Sales 2027 * 209x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Rezolute Inc

Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-14.41% - - 483M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.82%-1.93%+57.77%+191.52% 31.33B
Weighted average by Cap. -1.93%-1.50%+53.73%+151.51%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.86M 1.7M 3.2M 220M 3.21M 22.09M 8.62M 111M 8.65M 8.46M 369M
Net income -72.7M -62.64M -58.73M -53.62M -101M -6.95B -101M -697M -272M -3.51B -273M -267M -11.63B -75.12M -64.73M -60.69M -55.4M -104M -7.18B -105M -720M -281M -3.62B -282M -276M -12.02B
Net Debt - -
Logo Rezolute Inc
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-